Co-Targeting CDK4/6 and AKT with Endocrine Therapy Prevents Progression in CDK4/6 Inhibitor and Endocrine Therapy-Resistant Breast Cancer

The authors showed that triple inhibition with fulvestrant, CDK4/6i and AKT inhibitor durably impaired growth of breast cancer cells, prevented progression and reduced metastasis of tumor xenografts resistant to CDK4/6i-fulvestrant combination or fulvestrant alone.